Faron receives EUR 2.1 million funding from BF
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron receives €2.1 million funding from Business Finland for Traumakine manufacturing Company announcement, 15 June 2020 at 9.00 AM (EET)Insider information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to initiate a new state of the art process for the manufacturing of interferon (IFN) beta-1a. To support this, Faron has received a €2,100,000 low interest rate loan from Business Finland, the governmental innovation financing